Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for ...

The top five submissions were combined into a super-algorithm for analyzing MRI scans for prostate cancer. Finally, AI assessments were compared to those of a group of radiologists on four hundred ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...